Relmada Therapeutics (RLMD) Change in Accured Expenses (2014 - 2026)
Relmada Therapeutics (RLMD) reported Change in Accured Expenses of -$1.6 million for Q1 2026, up 28.94% year-over-year from -$1.2 million in Q1 2025, and down 238.6% on a QoQ basis from $1.1 million in Q4 2025.
Relmada Therapeutics (RLMD) has 13 years of Change in Accured Expenses data on file, last reported at -$1.6 million in Q1 2026.
- Quarterly Change in Accured Expenses rose 28.94% year-over-year to -$1.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$664189.0 (up 79.29% YoY) and the FY2025 annual result came in at -$1.3 million, up 48.61% from the prior year.
- Change in Accured Expenses fell to -$1.6 million in Q1 2026 per RLMD's latest filing, from $1.1 million in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $6.6 million in Q2 2022 and bottomed at -$3.1 million in Q4 2022.
- The 5-year median for Change in Accured Expenses is -$193775.0 (2025), against an average of -$33305.9.
- The widest annual swing landed in 2022, when Change in Accured Expenses surged 664.92%; it then tumbled 1143.14% in 2024.
- Tracing RLMD's Change in Accured Expenses over 5 years: stood at -$3.1 million in 2022, then jumped by 199.33% to $3.1 million in 2023, then slumped by 86.57% to $419607.0 in 2024, then jumped by 168.13% to $1.1 million in 2025, then sank by 238.6% to -$1.6 million in 2026.
- Per Business Quant, the three latest RLMD Change in Accured Expenses figures stand at -$1.6 million (Q1 2026), $1.1 million (Q4 2025), and -$36140.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 931,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 70.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -176.03 Mn |
| 10 | Relmada Therapeutics | 595.35 Mn | 595.35 Mn | - | -1.56 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.56 Mn |
| Mar 31, 2026 | -1.56 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | -36,140.00 |
| Sep 30, 2025 | -36,140.00 |
| Jun 30, 2025 | -193,775.00 |
| Jun 30, 2025 | -193,775.00 |
| Mar 31, 2025 | -2.19 Mn |
| Mar 31, 2025 | -2.19 Mn |
| Dec 31, 2024 | 419,607.00 |
| Dec 31, 2024 | 419,607.00 |
| Sep 30, 2024 | 378,940.00 |
| Sep 30, 2024 | 378,940.00 |
| Jun 30, 2024 | -1.81 Mn |
| Jun 30, 2024 | -1.81 Mn |
| Mar 31, 2024 | -1.52 Mn |
| Mar 31, 2024 | -1.52 Mn |
| Dec 31, 2023 | 3.12 Mn |
| Dec 31, 2023 | 3.12 Mn |
| Sep 30, 2023 | -283,384.00 |
| Sep 30, 2023 | -283,384.00 |
| Jun 30, 2023 | 173,558.00 |
| Jun 30, 2023 | 173,558.00 |
| Mar 31, 2023 | -1.53 Mn |
| Mar 31, 2023 | -1.53 Mn |
| Dec 31, 2022 | -3.14 Mn |
| Dec 31, 2022 | -3.14 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | 6.64 Mn |
| Jun 30, 2022 | 6.64 Mn |
| Mar 31, 2022 | 870,905.00 |
| Mar 31, 2022 | 870,905.00 |
| Dec 31, 2021 | -1.67 Mn |
| Dec 31, 2021 | -1.67 Mn |
| Sep 30, 2021 | 2.08 Mn |
| Sep 30, 2021 | 2.08 Mn |
| Jun 30, 2021 | -1.18 Mn |
| Jun 30, 2021 | -1.18 Mn |
| Mar 31, 2021 | 379,601.00 |
| Mar 31, 2021 | 379,601.00 |
| Dec 31, 2020 | 1.60 Mn |
| Dec 31, 2020 | 1.60 Mn |
| Sep 30, 2020 | 1.30 Mn |
| Sep 30, 2020 | 1.30 Mn |
| Jun 30, 2020 | 202,565.00 |
| Jun 30, 2020 | 202,565.00 |
| Mar 31, 2020 | 333,432.00 |
| Mar 31, 2020 | 333,432.00 |
| Dec 31, 2019 | -492,919.00 |
| Dec 31, 2019 | -492,919.00 |
| Sep 30, 2019 | -303,465.00 |
| Sep 30, 2019 | -303,465.00 |
| Jun 30, 2019 | -72,692.00 |
| Jun 30, 2019 | -72,692.00 |
| Mar 31, 2019 | -369,598.00 |
| Mar 31, 2019 | -369,598.00 |
| Dec 31, 2018 | 2.02 Mn |
| Dec 31, 2018 | 2.02 Mn |
| Sep 30, 2018 | 306,706.00 |
| Sep 30, 2018 | 306,706.00 |
| Mar 31, 2018 | -35,513.00 |
| Mar 31, 2018 | -35,513.00 |
| Dec 31, 2017 | 92,525.00 |
| Dec 31, 2017 | 92,525.00 |
| Sep 30, 2017 | -42,251.00 |
| Sep 30, 2017 | -42,251.00 |
| Jun 30, 2017 | -231,201.00 |
| Jun 30, 2017 | -231,201.00 |
| Mar 31, 2017 | 113,962.00 |
| Mar 31, 2017 | 113,962.00 |
| Dec 31, 2016 | 67,594.00 |
| Dec 31, 2016 | 67,594.00 |
| Sep 30, 2016 | -229,967.00 |
| Sep 30, 2016 | -229,967.00 |
| Jun 30, 2016 | -410,840.00 |
| Jun 30, 2016 | -410,840.00 |
| Mar 31, 2016 | -516,983.00 |
| Mar 31, 2016 | -516,983.00 |
| Dec 31, 2015 | 948,145.00 |
| Dec 31, 2015 | 948,145.00 |
| Sep 30, 2015 | 132,264.00 |
| Sep 30, 2015 | 132,264.00 |
| Jun 30, 2015 | -16,223.00 |
| Jun 30, 2015 | -16,223.00 |
| Mar 31, 2015 | -123,194.00 |
| Mar 31, 2015 | -123,194.00 |
| Dec 31, 2014 | -357,813.00 |
| Dec 31, 2014 | -357,813.00 |
| Sep 30, 2014 | 497,474.00 |
| Sep 30, 2014 | 497,474.00 |
| Jun 30, 2014 | 4,287.00 |
| Jun 30, 2014 | 4,287.00 |
| Mar 31, 2014 | 248,840.00 |
| Mar 31, 2014 | 248,840.00 |